Back to search
FDAFDA · Food and drugs·Recall number D-0166-2025

UMARY ACID HYALURONIC, 850 MG CAPLETS, 30-count bottle, UPC7502265120323

Published January 1, 2025 · Recall initiated: November 14, 2024

Summary

FDA records drug Class II recall D-0166-2025, published January 1, 2025 and initiated November 14, 2024. Recalling firm: MXBBB; Status: Ongoing; Reported quantity: 321 bottles; Lot: Lot#: 24183, Exp 07/01/28. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP Deviations: the firm initiated a recall after notification from the distributor that product may be tainted with undeclared diclofenac and omeprazole, however there is no analytical data confirming that product distributed by the firm is tainted.

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
MXBBB
Distributor
Product was sold via Amazon Marketplace.
UPC
7502265120323
Lot
Lot#: 24183, Exp 07/01/28
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was UMARY ACID HYALURONIC, 850 MG CAPLETS, 30-count bottle, UPC7502265120323 recalled?

Yes. FDA published recall D-0166-2025 on January 1, 2025. Reported hazard: cGMP Deviations: the firm initiated a recall after notification from the distributor that product may be tainted with undeclared diclofenac and omeprazole, however there is no analytical data confirming that product distributed by the firm is tainted.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release

How do I know if my unit is part of the recall?

Compare your product details with the notice. UPC: 7502265120323.